XML 81 R36.htm IDEA: XBRL DOCUMENT
v3.23.3

Earnings Per Share (Tables) | 12 Months Ended
--- | ---
Sep. 30, 2023
Earnings Per Share [Abstract] |
Schedule of Earnings Per Share, Basic and Diluted | The following table presents the computation of basic and diluted earnings per share for the years ended September 30, 2023, 2022 and 2021.
|  | Year Ended September 30,
|  | 2023 |  | 2022 |  | 2021
|  | (in thousands, except per share amounts)
Numerator: |  |  |  |  |  |
Net loss attributable to Arrowhead Pharmaceuticals, Inc. |  | $ | (205,275) |  |  | $ | (176,063) |  |  | $ | (140,848) |
Denominator: |  |  |  |  |  |
Weighted-average basic shares outstanding |  | 106,750 |  |  | 105,426 |  |  | 103,745 |
Effect of dilutive securities |  | — |  |  | — |  |  | — |
Weighted-average diluted shares outstanding |  | 106,750 |  |  | 105,426 |  |  | 103,745 |
Basic earnings per share |  | $ | (1.92) |  |  | $ | (1.67) |  |  | $ | (1.36) |
Diluted earnings per share |  | $ | (1.92) |  |  | $ | (1.67) |  |  | $ | (1.36) |

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1 + Details
Name: | us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration